medscape.com
Cure8 news brief
Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's? - Medscape
Medications
Ustekinumab
Vedolizumab
Anti-TNF
IL-12/23 inhibitor
Anti Integrin
Fecal calprotectin
CRP
Why This Matters
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF agents in this cohort.
The report also notes benefits for some with perianal disease and reductions in fecal calprotectin.
Who Should Pay Attention
Adult patients with Crohn's disease who have failed anti‑TNF or vedolizumab, patients on biologics, gastroenterologists, and researchers studying biologic sequencing.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This study compared real-world persistence and clinical outcomes for patients switched to ustekinumab after failing anti‑TNF or vedolizumab. More patients stayed on ustekinumab at 1–3 years versus historical anti‑TNF persistence in the cohort, and clinical remission rates and fecal calprotectin declined over time.
A minority required dose optimization; a small subset discontinued for nonresponse or adverse events. Some patients with perianal disease achieved remission and fistula healing.
How to use this: This is observational, single‑center data—not a randomized trial—so it can inform conversations with clinicians about treatment sequencing and expectations, but does not establish superiority. Discuss individual risks, monitoring, and prior treatment history with your care team.
Keep In Mind
This is a retrospective, single‑center observational study with a small sample size and limited colonoscopy data; results are hypothesis‑generating rather than definitive. The article summarizes a peer‑reviewed publication in Digestive Diseases and Sciences; talk with your clinician before making treatment changes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmedscape.com
Indexed viaGoogle News
Source typeResearch news
PublishedMar 28, 2025, 12:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...